We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
- Authors
Chung, C H; Aulino, J; Muldowney, N J; Hatakeyama, H; Baumann, J; Burkey, B; Netterville, J; Sinard, R; Yarbrough, W G; Cmelak, A J; Slebos, R J; Shyr, Y; Parker, J; Gilbert, J; Murphy, B A
- Abstract
Our previous study has shown that nuclear factor-kappa B (NF-kappaB)-signaling pathway was associated with a higher rate of recurrence in head and neck squamous cell carcinoma (HNSCC). The combination of bortezomib, an NF-kappaB inhibitor by inhibition of proteasomes, plus docetaxel was assessed for efficacy and toxicity.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Vol 21, Issue 4, p864
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdp390